Diamyd Medical (DMYD) Company Presentation summary

Mission and medical need

• Focused on curing Type 1 Diabetes through precision medicine and immunotherapy targeting genetic subgroups.

• Addresses a significant unmet need with over 500,000 new cases annually and a $90 billion economic burden.

• Aims to extend health and life span by reducing risks of cardiovascular and other complications.

Product and clinical pipeline

• Lead candidate DiamydⓇ targets HLA DR3-DQ2 positive Type 1 Diabetes, covering about 40% of patients.

• Phase 3 trial (DIAGNODE-3) underway for Stage 3 T1D; Phase 2 for Stages 1 & 2 and adult-onset T1D/LADA.

• Discovery program in place for HLA DR4-DQ8 positive patients, expanding the addressable population.

• DiamydⓇ is administered via three targeted intranodal injections, outpatient procedure.

Clinical efficacy and safety

• Over 1,000 patients treated in 16 trials; favorable safety profile with <1% drop-out in targeted administration.

• Statistically significant preservation of C-peptide and improved HbA1c in HLA DR3-DQ2 positive patients.

• Meta-analyses show up to 56% reduction in C-peptide decline and improved glycemic control in responders.

• Exploratory analyses confirm benefits in continuous glucose monitoring outcomes.